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Fibromyalgia is “a painful musculoskeletal disorder characterized by widespread
chronic pain as a core clinical feature associated with fatigue, non-refreshed
sleep, and morning stiffness in more than 75% of cases, paraesthesia, irritable
bowel syndrome, functional disability in 25% of cases”. This definition poses
a clinical misunderstanding and a pathophysiologic challenge as in “fibromyal-
gia”, the emphasis is focused on the muscle and on pain. This may lead many
doctors to consider the muscle as a treatment target. On the other side, its patho-
physiology is still a challenge even if several lines of research using both invasive
and non-invasive methodology assess a substantial integrity of the fibromyalgic
muscle. Moreover, several data confirm the presence of a central sensitization
posing fibromyalgia within the so-called central sensitization syndromes (CSS).
CSS are mediated by the central nervous system. Fibromyalgia and CCS are
clinically and physiologically characterized by: hyperalgesia (excessive sensi-
tivity to a normally painful stimulus), allodynia (painful sensation to a normally
non-painful stimulus), expansion of the receptive field (pain beyond the area
of peripheral nerve supply), prolonged electrophysiological discharge, and an
after-stimulus unpleasant quality of pain (e.g., burning, throbbing, tingling or
numbness). As to say in fibromyalgia: more brain than muscle.
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Pharmacological treatment in the fibromyalgia syndrome (FMS) is part of the
multimodal approach needed in this condition, but there is no evidence that
patients experience harm if they do not receive drugs. All drugs that have been
proven effective in randomized controlled clinical trials have, on average, low
effect sizes, which means that the gain in pain reduction, improvement of sleep,
depression or other fibromyalgia symptoms is mild to moderate compared to
a placebo treatment [1]. Nevertheless, drug treatment should not be withheld
from patients and should be administered using a shared-decision strategy. Treat-
ment should be adapted to an individual patient’s symptoms taking into account
co-morbidities and potential side effects. A drug should only be continued in
responders. At present, pregabalin, duloxetine, milnacipran and amitriptyline
are the current first-line agents. Recent data showing nociceptor pathology in
FMS patients [2] may explain the overlap of drugs used in FMS with those used
against neuropathic pain.
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During the past decades, the approach to treat patients with fibromyalgia was
sustained by osteoarticular theories; the Physical Rehabilitation and Medicine
(PRM) physician tried to support their patients using physical therapy according
attention to the tendons, the joints and/or the muscle.
Then, we considered the aerobic conditions of patients with fibromyalgia and
created programs with land- or water-based aerobic physical activity. At this
stage, the PRM physician was considered like a cardiologist, a physiologist or
a personal trainer.
Within the last 3 years, many studies confirmed our impression that the leading
cause for fibromyalgia was probably located in the brain and involved many
processes, like immunologic-modulation, pain-modulation, cardiorespiratory
dysfunction.
In consequence, the PRM physician tends to become a new super doctor with
superpowers, treating the muscle, the heart, the lungs and also – what a supreme
consecration – the whole brain with his so complex mechanisms.
A new era is opened for the physical medicine and rehabilitation with an evolu-
tion from the muscle to the brain, using aerobic exercise, Tai Chi, Nordic walking,
Spa therapy or acupuncture. The condition for success is to treat and follow our
patient for a long time and within an individually customized program.
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Fibromyalgia is a syndrome of unknown etiology characterized by chronic pain,
decreased pain threshold, trigger points, fatigue, disturbed sleep, stiffness, cog-
nitive dysfunction, anxiety and depression. Fibromyalgia severity level was
significantly associated with patients’ health status and core symptom domains.
But the social consequences of fibromyalgia can often be more challenging than
the limitations patients experience with body functions and activities. Patients
report disrupted relationships with family and friends, social isolation, reduced
activities of daily living and leisure activities, avoidance of physical activity,
and loss of career. Patients’ functioning is influenced by their interaction with
the environment and their own personal characteristics, not only by the health
condition. From the patients’ perspective, fibromyalgia is more than a painful
condition. It is associated with many symptoms and has a substantially negative
impact on function and quality of life. Despite the difficulty of finding standard-
ized measures, a comprehensive assessment of the multiple symptoms domains
associated with fibromyalgia and the impact of fibromyalgia on multidimen-
sional aspects of function should be a routine part of the care of fibromyalgia
patients in the clinic and in trials of fibromyalgia treatment.
http://dx.doi.org/10.1016/j.rehab.2014.03.946
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Introduction.– The objective was to investigate trajectories of purchases of
prescribed pain medications (PPM) amongst people with fibromyalgia during
9 years around multidisciplinary rehabilitation.
Material and methods.– Register-based study of 302 participants. Purchases of
PPM were measured in a 9-year exposure window ranging from four year before
the year of rehabilitation to four year afterwards. Mean values of annual pur-
chases were calculated in daily-defined doses. Annual changes in purchases
before and after rehabilitation were estimated by rate ratios and their 95%
confidence intervals.
Results.– Consumption of analgesics, antidepressants, hypnotics and sedatives,
and muscle relaxants was greater in the last year than the first year of the 9-
year trajectory. The growth in PPM consumption was steep in the years before
rehabilitation but hindered at the time of rehabilitation. The rate ratios of annual
consumption of PPM declined in the period after the rehabilitation, e.g. from
1.31 to 1.00 for analgesics.
Discussion.– Association between multidisciplinary rehabilitation and slow-
ing increase of PPM consumption were observed amongst rehabilitants with
fibromyalgia. It is possible that this change reflects a good rehabilitation result
continuing years after rehabilitation.
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Objective.– In this study, we analysed serum trace element levels in fibromyalgia
syndrome (FMS) patients and its correlation with clinical parameters.
Patients and methods.– Forty patients diagnosed as having FMS according to
ACR 1990 criteria and 35 healthy subjects were enrolled in this study. Patient
group was evaluated for age, disease duration, body mass index, medication,
medical history, visual analogue scale (VAS), morning stiffness, fatigue, sleep-
ing disorders, number of tender points, short form-36 (SF-36), fibromyalgia
impact questionnaire (FIQ), Beck depression inventory (BDI). In the laboratory
examination, serum copper (Cu), zinc (Zn), selenium (Se) and magnesium (Mg)
levels were measured.
Results.– No significant difference was found in the demographic features
between two groups. The serum levels of Cu (mean 91.16g/dL), Zn (mean
135.86g/dL) and Mg (mean 1.94 mg/dL) were determined as normal range. In
FMS patients, serum levels of Cu, Zn and Mg were similar to the control group.
However, serum Se levels (mean 50.53g/dL) were significantly decreased com-
pared with healthy subjects (P < 0.01). There was correlation between serum Se
levels and disease duration, VAS, number of tender points.
Conclusion.– Our findings demonstrated there was the link between serum Se
levels and some clinical findings of FMS.
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Introduction.– Fibromyalgia syndrome (FMS) is characterized by chronic
widespread pain, fatigue, tenderness on palpation and sleep disturbances. The
optimal aerobic exercise (AE) type in this condition is not established. There-
fore, the aim of this study was to evaluate the efficacy of different types of AE
in FMS.
Materials and methods.– Systematic review of the literature on AE in FMS
published until October 2013 in MEDLINE, Cochrane Library, EMBASE and
Scopus databases.
Results.– Twenty-eight randomized controlled trials (RCTs) comparing AE with
controls (treatment as usual, placebo, active therapy) and seven RCTs comparing
different types of AE were analyzed (2494 patients). AE improved physical
fitness (0.65; P < 0.001) and reduced pain (–0.31; P < 0.001), fatigue (–0.22;
P = 0.009), depressed mood (–0.32; P = 0.002) and limitations of health-related
quality of life (HRQOL) (–0.40; P < 0.001). Positive effects could be maintained
at follow-up. Land-based and water-based AE (exercises with slight to moderate
intensity; two or three times per week) reduced significantly pain.
Discussion.– Aerobic exercise programme (land-based or water-based exercises,
with slight to moderate intensity, two or three times per week, for at least 4 weeks)
should be recommended for FMS patients.
http://dx.doi.org/10.1016/j.rehab.2014.03.949
